(Q38462688)

3 September 2017

title

The JUPITER trial: myth or reality? (English)

1 reference

3 September 2017

Ryan P Morrissey

1

1 reference

3 September 2017

George A Diamond

series ordinal

2

1 reference

3 September 2017

Sanjay Kaul

series ordinal

3

1 reference

3 September 2017

language of work or name

1 reference

1 October 2011

1 reference

Current Atherosclerosis Reports

3 September 2017

published in

1 reference

3 September 2017

volume

13

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

413-421

1 reference

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

By Jove! What is a clinician to make of JUPITER?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

The JUPITER trial: results, controversies, and implications for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Lipid lowering for primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

The JUPITER Trial: responding to the critics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Early stopping of randomized clinical trials for overt efficacy is problematic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Stopping at nothing? Some dilemmas of data monitoring in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Statin-associated memory loss: analysis of 60 case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prev

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Gauging the impact of statins using number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0197-9

Cost-minimization and the number needed to treat in uncomplicated hypertension

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21789573

12 December 2020

inferred from PubMed ID database lookup

Statins for the primary prevention of cardiovascular disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21789573

12 December 2020

inferred from PubMed ID database lookup

The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21789573

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11883-011-0197-9

1 reference

Dimensions Publication ID

3 September 2017

1051655028

0 references

Fatcat ID

release_fynrw7pazng43ews33sk4rpfnq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fynrw7pazng43ews33sk4rpfnq

24 November 2022

mapped directly with Wikidata item

1 reference